Allergan wants to buy a Cambridge biotech founded by ex-Genzyme CEO

Allergan has purchased the right to acquire small Cambridge-based biotech Lysosomal Therapeutics for an undisclosed sum, the Irish drugmaker said on Monday.Allergan (NYSE: AGN) said it had purchased the option to buy Lysosomal following the completion of a Phase 1B trial of the Cambridge firm’s lead drug, a treatment for Parkinson's disease.Lysosomal, an 18-person company co-founded by former Genzyme CEO Henri Termeer, is named for the enzyme deficiency in a set of cells known as the lysos